Overall Survival: Subgroup Analyses

SubgroupNumber of Evaluable Patients

Hazard Ratio (95% CI)Ruxolitinib Placebo

Primary MF 70 84 0.65 (0.29–1.47)

Post-Polycythemia Vera-MF 50 47 0.25 (0.05–1.20)

Post-Essential Thrombocythemia-MF 35 22 1.12 (0.10–12.4)

IPSS Risk - High 90 99 0.55 (0.26–1.18)

IPSS Risk – Int-2 64 54 0.45 (0.11–1.87)

Age ≤65 Years 52 70 0.22 (0.06–0.84)

Age >65 Years 85 102 0.75 (0.34–1.66)

JAK2V617F Mutation Positive 113 123 0.56 (0.25–1.27)

JAK2V617F Mutation Negative 40 27 0.34 (0.09–1.37)

Baseline Spleen Length ≤10cm 32 27 0.67 (0.11–4.03)

Baseline Spleen Length >10cm 123 126 0.49 (0.23–1.01)

Baseline Hb ≥10g/dL 84 78 0.37 (0.10–1.42)

Baseline Hb <10g/dL 71 76 0.59 (0.27–1.29)